Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies.
- Author:
Sang Hoon HAN
1
Author Information
- Publication Type:Review
- Keywords: Cell-mediated immunity; Cytomegalovirus; Immune monitoring; Solid organ transplantation
- MeSH: Antibodies, Monoclonal; Cytomegalovirus*; Enzyme-Linked Immunospot Assay; Flow Cytometry; Graft Survival; Immunity, Cellular; Immunophenotyping; Major Histocompatibility Complex; Methods; Monitoring, Immunologic; Organ Transplantation*; Transplants*
- From:Infection and Chemotherapy 2017;49(3):161-175
- CountryRepublic of Korea
- Language:English
- Abstract: The current cytomegalovirus (CMV) prevention strategies in solid organ transplantation (SOT) recipients have contributed towards overcoming the detrimental effects caused by CMV lytic infection, and improving the long-term success rate of graft survival. Although the quantification of CMV in peripheral blood is the standard method, and an excellent end-point for diagnosing CMV replication and modulating the anti-CMV prevention strategies in SOT recipients, a novel biomarker mimicking the CMV control mechanism is required. CMV-specific immune monitoring can be employed as a basic tool predicting CMV infection or disease after SOT, since uncontrolled CMV replication mostly originates from the impairment of immune responses against CMV under immunosuppressive conditions in SOT recipients. Several studies conducted during the past few decades have indicated the possibility of measuring the CMV-specific cell-mediated immune response in clinical situations. Among several analytical assays, the most advancing standardized tool is the QuantiFERON®-CMV assay. The T-Track® CMV kit that uses the standardized enzyme-linked immunospot assay is also widely employed. In addition to these assays, immunophenotyping and intracellular cytokine analysis using flow cytometry (with fluorescence-labeled monoclonal antibodies or peptide-major histocompatibility complex multimers) needs to be adequately standardized and validated for potential clinical applications.
